Elravie Premier creates a surprisingly difficult buying question. Cytollia’s current Light-L, Deep Line-L and Ultra Volume-L options map to Humedix 1 mL pages with the same headline formula: 23 mg/mL hyaluronic acid and 0.3% lidocaine. If the concentration and syringe size are the same, what actually gives the three products different jobs—and which ones deserve space in a clinic’s first order?
Quick answer
Choose Elravie Premier by product role and clinic demand, not HA concentration alone. Regulatory documents list overlapping but rising dynamic-viscosity ranges for Light-LC, Deep Line-LC and Ultra Volume-LC, while their registered 1 mL kits use different needle and cannula combinations. Cytollia translates that structure into three clinic roles: Refine, Core and Define. For a clinic testing the family, Deep Line is the most practical first SKU to evaluate; add Light when refinement services dominate, or Ultra Volume when contour-led demand is already proven.
Why the usual area chart is not enough
Most Elravie pages make the range look effortless: Light for fine work, Deep Line for deeper correction and Ultra Volume for volume. That summary is easy to scan, but it leaves the most useful professional question unanswered. A clinic does not stock a facial area. It stocks a product that needs a clear job, a repeatable consultation story and enough demand to earn its reorder point.
The names are therefore a starting clue, not the complete selection logic. All three current 1 mL products share the same HA concentration and lidocaine percentage. What changes is the product-property range and the registered delivery set. This is why Elravie cannot be understood as “more HA” from Light to Ultra Volume—and why a copied low/medium/high chart does not provide enough information for purchasing.
The Elravie Premier decision matrix
| Current Cytollia option | Published dynamic-viscosity range | Registered 1 mL kit | Cytollia clinic role |
|---|---|---|---|
| Light-L Humedix page: Light-LC |
20,000-40,000 mPa·s | Two 30G thin-wall needles | Refine: the lower product-property position for a menu built around subtle finishing goals |
| Deep Line-L Humedix page: Deep Line-LC |
25,000-50,000 mPa·s | One 27G thin-wall needle and one 23G × 50 mm cannula | Core: the central range position and the most practical first SKU to evaluate |
| Ultra Volume-L Humedix page: Ultra Volume-LC |
30,000-60,000 mPa·s | One 23G thin-wall needle and one 22G × 50 mm cannula | Define: the upper product-property position for a contour-led service mix |
All three current Humedix 1 mL pages list 23 mg/mL HA and 0.3% lidocaine. Dynamic viscosity and registered kits are product attributes, not a clinical ranking or an injection protocol. Export packaging can vary, so the received box and current product instructions remain the final package reference.
Same concentration, different product jobs
The useful Elravie insight is not simply that the three viscosity ranges rise. It is that they overlap. Light reaches 40,000 mPa·s, Deep Line spans 25,000-50,000 mPa·s and Ultra Volume begins at 30,000 mPa·s. That overlap makes a rigid weak-medium-strong ranking misleading. It suggests a related family whose product positions move across a shared physical-property spectrum.
Huons Global describes Elravie Premier as a line segmented by physical properties and attributes the family to Humedix’s Hi-B technology, which is intended to improve crosslinking efficiency while maintaining the inherent viscosity of HA. That manufacturer-level story explains why concentration alone is not the selector. It does not, however, turn one viscosity number into a guaranteed result.
For the clinic, the commercial translation is straightforward: the three products need distinct roles. If two SKUs are being used for the same consultation promise, one of them may be occupying shelf space without a real job. If the team can explain when the menu shifts from refinement to a core correction goal and then to stronger definition, the range becomes easier to train, quote and reorder.
Clinic Fit Map
Best fit
Clinics that want a compact three-position HA range and prefer to add one outer role around a central SKU rather than immediately carrying four or more variants.
Strong starting fit
Teams that can begin with Deep Line, measure whether consultations lean toward refinement or definition, and let that evidence determine the second SKU.
Potential mismatch
Clinics that want one product to cover every service or that stock a complete range for display before proving demand for each role.
Treatment Menu Builder: Refine, Core and Define
Customers do not need to choose between Light, Deep Line and Ultra Volume from a product chart. They need to understand the treatment goal. Cytollia’s clinic menu framework keeps the customer-facing decision simple while preserving professional product selection behind it.
Refine
A consultation language for subtle finishing goals and the lower product-property position in the Elravie range. Light becomes a professional product option behind that menu, not the name of the service itself.
Core
The clinic’s central correction role and the clearest place to begin evaluating Elravie. Deep Line sits in the middle documented band and gives the team one anchor before it expands outward.
Define
A contour- and definition-led menu position for clinics that already see recurring demand at the upper end of the range. Ultra Volume earns shelf space when this is a real service category, not merely because it is the highest-named option.
This is more persuasive than selling “low, medium and high viscosity.” It lets a clinic market three understandable goals while the practitioner chooses the exact product after assessment. It also avoids the common consultation problem in which “Ultra Volume” sounds automatically better or more expensive even when it is not the right role.
Which Elravie should a clinic stock first?
Deep Line is the most practical first Elravie SKU to evaluate commercially. It occupies the centre of the published viscosity ranges, appears in a product-specific laboratory study and has a registered kit containing both a needle and a cannula. This is not a claim that Deep Line is clinically universal. It is a purchasing conclusion: one central role gives a clinic the clearest baseline from which to observe actual demand.
| Clinic demand pattern | Practical Elravie start | Why this mix is efficient |
|---|---|---|
| Testing Elravie with a focused menu | Deep Line first | Creates one central benchmark before cash is spread across all three variants. |
| Refinement-heavy consultation mix | Light + Deep Line | Adds a lower role while keeping the range compact and easy to train. |
| Contour- and definition-heavy mix | Deep Line + Ultra Volume | Adds the upper position only where recurring structural demand can support reorders. |
| Established broad filler menu | All three variants | Gives Refine, Core and Define their own stock line when both outer roles already sell. |
Because Cytollia’s current options are each a single 1 mL syringe, the box, syringe and nominal-millilitre comparison starts from the same unit. That makes Elravie’s stock architecture easier to read than a family with mixed one- and two-syringe boxes. The decision is less about normalizing pack size and more about whether each role generates enough consultations to justify its own reorder point.
Why the kit differences matter to a buyer
The registered 1 mL configurations change visibly across the family: Light lists two 30G needles, Deep Line lists a 27G needle plus a 23G cannula, and Ultra Volume lists a 23G needle plus a 22G cannula. These are not decorative packaging differences. They help purchasing and receiving teams confirm that a quoted variant, delivered box and internal stock record refer to the same product.
They can also affect clinic preparation and staff familiarity, which is why the exact SKU should never be shortened to “Elravie” on a quotation or inventory sheet. The kit does not tell a practitioner how a product must be injected; it tells the buyer that the three boxes were designed and registered as distinct configurations. If an export box differs from the configuration shown here, document the supplied contents rather than silently merging it with another SKU.
How Elravie’s stock logic differs from Chaeum and Dermalax
Cytollia’s current Chaeum Premium family offers four numbered roles in two-syringe, 2.2 mL boxes. Dermalax offers three products but changes from one-syringe boxes to a two-syringe Implant Plus box. Elravie Premier takes a different route: three named options, each represented as one 1 mL selection in the current Cytollia listing.
That makes Elravie the cleanest of the three families for a core-plus-one stocking strategy. A clinic can evaluate Deep Line, add one outer role and compare the variants without pack-count distortion. Chaeum may suit a team that wants a broader four-step menu; Dermalax creates a stronger unit-economics question at the top of its range; Elravie keeps the commercial unit consistent and puts the emphasis on product role.
Consultation Talking Points
- “The three products contain the same headline amount of HA, but they are designed for different roles.” This keeps the explanation accurate without asking a customer to interpret viscosity.
- “We choose the product after we understand the result you want.” The menu goal comes first; the professional product decision follows.
- “Ultra Volume is not automatically the best choice.” It is the upper product-property position, while Light and Deep Line have different jobs.
- “Your plan is built around anatomy and the service goal, not the name on the box.” This keeps the conversation focused on value rather than product hierarchy.
What the Deep Line study adds—and what it does not
A 2024 peer-reviewed laboratory paper included one Elravie Premier Deep Line batch among five HA fillers and compared rheology with four cohesion tests. That gives Deep Line something many distributor descriptions omit: named, product-specific research rather than a generic claim about HA fillers.
The most useful finding for a buyer was the authors’ broader warning. Rheology alone did not fully describe filler behaviour, and cohesion still lacks one standardized test. In practical terms, the published viscosity bands help explain why the Elravie variants occupy different positions, but they should not be converted into a promise that one product will always perform, feel or last a certain way. The study applies to the tested Deep Line sample; it is not proof for Light or Ultra Volume.
Results, duration and common questions
Elravie Premier is a temporary crosslinked HA filler family. The visible result and how long it remains noticeable depend on the exact product, service plan, anatomy, movement and individual response. Many marketplace pages repeat one duration range across the full family, but a clinic should set expectations from the exact product documentation and its own approved consultation process rather than promise one number for all three variants.
Are Light, Deep Line and Ultra Volume the same because all three are 23 mg/mL?
No. The concentration, lidocaine percentage and syringe volume are shared, while the documented dynamic-viscosity ranges and registered kits differ.
Is Ultra Volume the strongest or best Elravie Premier filler?
It occupies the upper documented range, but “best” is the wrong purchasing question. The right option depends on the clinic role and the professionally assessed service goal.
Is Deep Line the best first purchase?
It is Cytollia’s preferred commercial evaluation point because it occupies the centre of the range. That does not make it a universal clinical substitute for Light or Ultra Volume.
Does a clinic need all three products?
No. A focused clinic can begin with Deep Line and add Light or Ultra Volume according to real consultation demand. The complete range makes sense when both outer roles already earn repeat business.
Why does Cytollia use “-L” while Humedix’s English pages show “-LC”?
Cytollia follows the labels on its current export boxes, while the reviewed Humedix English pages use the LC suffix. Keep the full variant name on quotations, receiving records and stock entries so the supplied product can be matched correctly.
Build your Elravie Premier range
Start with the role your clinic already sells, then let live demand decide whether the range needs Refine, Core, Define—or all three. Cytollia’s current Elravie Premier product keeps Light-L, Deep Line-L and Ultra Volume-L together so a buyer can compare availability and tier pricing without searching across separate listings.
Related Clinic-Ready Guides
- Chaeum Premium No.1-No.4: Uses, Treatment Goals and Clinic Guide
- Dermalax Plus vs Deep Plus vs Implant Plus: What Should a Clinic Stock?
Sources and commercial disclosure
- Humedix: Elravie Premier Light-LC 1 mL
- Humedix: Elravie Premier Deep Line-LC 1 mL
- Humedix: Elravie Premier Ultra Volume-LC 1 mL
- Roszdravnadzor: active Elravie Premier registration and 1 mL kit configurations
- Roszdravnadzor public documentation: dynamic-viscosity ranges
- Huons Global: Humedix HA filler technology and Elravie Premier Hi-B background
- Huons Global 4Q24 IR Book: Elravie Premier physical-property segmentation
- Kim, Lee and Yang (2024): “Cohesiveness of Hyaluronic Acid Fillers”
Last verified: July 25, 2026. Cytollia sells the product linked from this guide. Live price, stock and tier pricing are commercial information and can change. Refine, Core and Define are Cytollia editorial menu roles created from the documented product differences; they are not manufacturer indications or a claim of clinical superiority.